[1]
|
Neven, A., Laven, J., Teede, H. and Boyle, J. (2018) A Summary on Polycystic Ovary Syndrome: Diagnostic Criteria, Prevalence, Clinical Manifestations, and Management According to the Latest International Guidelines. Seminars in Reproductive Medicine, 36, 5-12. https://doi.org/10.1055/s-0038-1668085
|
[2]
|
Xu, Y. and Qiao, J. (2022) Association of Insulin Resistance and Elevated Androgen Levels with Polycystic Ovarian Syndrome (PCOS): A Review of Literature. Journal of Healthcare Engineering, 2022, Article ID: 9240569. https://doi.org/10.1155/2022/9240569
|
[3]
|
周圆, 王昕. 加减苍附导痰汤联合达英-35治疗多囊卵巢综合征Meta分析[J]. 辽宁中医药大学学报, 2022, 24(4): 210-216.
|
[4]
|
廖小莉. 达英35和优思悦治疗多囊卵巢综合征的疗效比较[J]. 智慧健康, 2024, 10(2): 99-102.
|
[5]
|
吴丽娟. 达英-35联合二甲双胍治疗多囊卵巢综合征的临床疗效[J]. 中国现代医生, 2021, 59(24): 78-81+85.
|
[6]
|
Feng, X., Cheng, S., Xu, S., Chen, X. and Zhou, X. (2024) Efficacy and Safety of Cangfu Daotan Decoction as an Adjuvant Treatment of Diane-35 for Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Heliyon, 10, e36959. https://doi.org/10.1016/j.heliyon.2024.e36959
|
[7]
|
Manzoor, S., Ganie, M.A., Amin, S., Shah, Z.A., Bhat, I.A., Yousuf, S.D., et al. (2019) Oral Contraceptive Use Increases Risk of Inflammatory and Coagulatory Disorders in Women with Polycystic Ovarian Syndrome: An Observational Study. Scientific Reports, 9, Article No. 10182. https://doi.org/10.1038/s41598-019-46644-4
|
[8]
|
李婧怡, 陈静, 王莹莹, 等. 苍附导痰汤治疗痰湿型多囊卵巢综合征的作用机制及临床应用研究进展[J]. 上海中医药大学学报, 2024, 38(5): 101-108.
|
[9]
|
蔡淑侠, 韩延华, 冯聪, 等. 韩延华教授诊治多囊卵巢综合征经验[J]. 长春中医药大学学报, 2017, 33(4): 563-565.
|
[10]
|
谈勇. 中医妇科学[M]. 北京: 中国中医药出版社, 2016: 648-655.
|
[11]
|
Xu, D., Lu, M., Liu, Y., Chen, W., Yang, X., Xu, M., et al. (2023) An Analysis of the Clinical Medication Rules of Traditional Chinese Medicine for Polycystic Ovary Syndrome Based on Data Mining. Evidence-Based Complementary and Alternative Medicine, 2023, Article ID: 6198001. https://doi.org/10.1155/2023/6198001
|
[12]
|
Harter, C.J.L., Kavanagh, G.S. and Smith, J.T. (2018) The Role of Kisspeptin Neurons in Reproduction and Metabolism. Journal of Endocrinology, 238, R173-R183. https://doi.org/10.1530/joe-18-0108
|
[13]
|
张飞祥, 李雪莲. 多囊卵巢综合征胰岛素抵抗机制研究进展[J]. 国际生殖健康/计划生育杂志, 2018, 37(2): 167-171.
|
[14]
|
马思明, 闫颖, 张晗. 苍附导痰汤对多囊卵巢综合征大鼠oatp4a1、代谢紊乱与肠道菌群的影响[J]. 天津中医药, 2023, 40(11): 1451-1456.
|
[15]
|
刘颖华, 王昕, 张阳, 等. 从脂代谢角度探讨苍附导痰汤治疗肥胖型多囊卵巢综合征大鼠的作用机制[J]. 时珍国医国药, 2023, 34(1): 6-9.
|
[16]
|
华诗芬, 张雯婷. 苍附导痰汤治疗多囊卵巢综合征作用机制的探析[J]. 中医临床研究, 2024, 16(29): 28-34.
|
[17]
|
Rudnicka, E., Suchta, K., Grymowicz, M., Calik-Ksepka, A., Smolarczyk, K., Duszewska, A.M., et al. (2021) Chronic Low Grade Inflammation in Pathogenesis of PCOS. International Journal of Molecular Sciences, 22, Article No. 3789. https://doi.org/10.3390/ijms22073789
|
[18]
|
Yi, W., Li, X., Chen, K., Zhu, M., Cai, X. and Pan, A. (2021) Effects of Cangfu Daotan Decoction on Obese Polycystic Ovary Syndrome and Its Mechanism. Steroids, 165, Article ID: 108740. https://doi.org/10.1016/j.steroids.2020.108740
|
[19]
|
吴晓贞, 何嘉仑, 曾蕾. 基于TLR-4/NF-κB信号通路探讨苍附导痰汤对痰湿型多囊卵巢综合征大鼠的治疗作用[J]. 中药新药与临床药理, 2022, 33(3): 307-312.
|
[20]
|
Pan, A., et al. (2015) Effects of Cangfu Daotan Decoction on Leptin and Adiponectin Levels and Insulin Sensitivity Index in Mice with Obese PCOS. Clinical Research on Traditional Chinese Medicine, 7, 4-6.
|
[21]
|
Li, G., Liu, Z., Ren, F., Shi, H., Zhao, Q., Song, Y., et al. (2022) Alterations of Gut Microbiome and Fecal Fatty Acids in Patients with Polycystic Ovary Syndrome in Central China. Frontiers in Microbiology, 13, Article ID: 911992. https://doi.org/10.3389/fmicb.2022.911992
|
[22]
|
周圆. 基于肠道菌群及血脂代谢探讨苍附导痰汤对痰湿证多囊卵巢综合征的干预作用[D]:[硕士学位论文]. 沈阳: 辽宁中医药大学, 2023.
|
[23]
|
姜晓琳, 刘静, 张阳, 等. 苍附导痰汤加二甲双胍联合穴位埋线对肥胖型多囊卵巢综合征不孕症患者免疫功能及肠道菌群的影响[J]. 临床误诊误治, 2020, 33(8): 51-56.
|
[24]
|
逯冰辉, 张宁. 自噬与多囊卵巢综合征关系的研究进展[J]. 中国性科学, 2023, 32(5): 80-83.
|
[25]
|
于晓娜, 连方, 相珊, 等. 基于miR-17-5p/ATG7介导自噬探讨苍附导痰汤对痰湿型多囊卵巢综合征不孕症的影响[J]. 中华中医药杂志, 2023, 38(10): 5075-5080.
|
[26]
|
韩波. 达英-35联合二甲双胍对多囊卵巢综合征的治疗效果及对血清生长激素释放肽、摄食抑制因子1的影响[J]. 世界复合医学, 2022, 8(4): 173-176, 181.
|
[27]
|
王子珺. 利拉鲁肽、达英-35结合来曲唑在多囊卵巢综合征不孕治疗中的作用[J]. 医学理论与实践, 2025, 38(3): 441-443.
|
[28]
|
杨珺, 杨芳, 阿丽萍. 达英-35联合苍附导痰汤治疗多囊卵巢综合征的临床研究[J]. 宁夏医学杂志, 2021, 43(5): 468-470.
|
[29]
|
高秀娟. 苍附导痰汤加减联合达英-35治疗多囊卵巢综合征效果观察[J]. 实用中医药杂志, 2019, 35(1): 93-94.
|
[30]
|
温灿良, 钟卓慧, 陈晶晶. 苍附导痰汤联合达英-35治疗多囊卵巢综合征临床观察[J]. 实用中医药杂志, 2018, 34(8): 939.
|
[31]
|
刘红霞. 苍附导痰汤加减联合达英-35治疗痰湿型多囊卵巢综合征的效果评价[J]. 甘肃科技, 2018, 34(12): 86-87.
|
[32]
|
孙玉香. 苍附导痰汤联合达英-35治疗痰湿型多囊卵巢综合征的临床观察[J]. 中医临床研究, 2018, 10(10): 71-72.
|
[33]
|
张莉, 陈鸿, 赖玉琴. 苍附导痰汤联合达英-35、克罗米芬治疗多囊卵巢不孕90例效果观察[J]. 武警后勤学院学报(医学版), 2018, 27(3): 241-243.
|
[34]
|
Wild, R.A., Carmina, E., Diamanti-Kandarakis, E., Dokras, A., Escobar-Morreale, H.F., Futterweit, W., et al. (2010) Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. The Journal of Clinical Endocrinology & Metabolism, 95, 2038-2049. https://doi.org/10.1210/jc.2009-2724
|
[35]
|
罗茜. 达英-35治疗多囊卵巢综合征的临床疗效分析[J]. 临床医药实践, 2010, 19(10): 591-593.
|